Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `amp_init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114

Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `amp_init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114

Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114

Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114
Recce Pharmaceuticals: Selects CMAX for phase I/II UTI clinical trial | Fintech InShorts: Latest fintech news, analysis by experts

Less than 1 min.Read

Recce Pharmaceuticals: Selects CMAX for phase I/II UTI clinical trial

By Steve Sam

February 20, 2023

Recce Pharmaceuticals Selects CMAX for phase I/II UTI clinical trial

Recce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility for a clinical trial to treat urinary tract infections (UTIs)
The phase one and two intravenous clinical trial will assess RCE’s lead drug candidate, R327, in UTIs, with dosing to commence this quarter
Recce will collect plasma and urine from 12 healthy males and females following dosing to evaluate R327’s concentrations and antibacterial effect in the urine on bacteria
It follows an independent in-vitro study that found R327 had a fast effect against E. coli bacteria, which is responsible for around 90 per cent of UTIs
Recce shares are trading at 58 cents at midday AEDT